Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported second-quarter net income of $1.1 million, after reporting a loss in the same period a year earlier.
On a per-share basis, the San Diego-based company said it had net income of 1 cent.
The results surpassed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 12 cents per share.
The drugmaker posted revenue of $165.2 million in the period, also beating Street forecasts. Eight analysts surveyed by Zacks expected $154.3 million.
Acadia shares have increased 83% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $29.20, a climb of 95% in the last 12 months.
https://finance.yahoo.com/news/acadia-q2-earnings-snapshot-202658911.html
Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.63 |
Change
-1.080(6.46%) |
Mkt cap ! $1.997B | |||
| Open | High | Low | Value | Volume |
| $16.61 | $16.65 | $15.54 | $8.354M | 529.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 830 | $15.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.74 | 1484 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |